What are the two types of tumors that have newly FDA-approved theranostics?

1. Neuroendocrine Tumors (NETs): Theranostics using Gallium-68 (Ga-68) labeled somatostatin analogs, such as Ga-68 DOTATATE and Ga-68 DOTATOC, for the imaging of somatostatin receptor-positive NETs. Then Lutetium-177 (Lu-177) DOTATATE (Lutathera) is used for the treatment of somatostatin receptor-positive NETs.

2. Prostate Cancer: F-18 piflufolastat (PYLARIFY) or Ga-68 gozetotide are used to identify and localize the prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Then Lu-177 vipivotide tetraxetan (PLUVICTO) is used to target the PSMA-positive cancer cells for targeted radionuclide therapy.

Congratulations - you have completed the Nuclear Medicine Chapter - you may want to review the key questions, by selecting Nuclear Medicine and then Key Questions.